Skip to main content

CORRECTION article

Front. Oncol., 27 November 2023
Sec. Pediatric Oncology
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1333273

Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients

This article is a correction to:

  1. Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients

    1. Read original article
Ema Mosleh*Ema Mosleh1*Stacy Snyder&#x;Stacy Snyder1†Ningying WuNingying Wu2Daniel N. WillisDaniel N. Willis1Rema MaloneRema Malone3Robert J. HayashiRobert J. Hayashi1
  • 1Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States
  • 2Biostatistics Shared Resource, Division of Public Health Sciences and Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States
  • 3Division of Pediatric Hematology/Oncology, St. Louis Children’s Hospital, St. Louis, MO, United States

A Corrigendum on
Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients

By Mosleh E, Snyder S, Wu N, Willis DN, Malone R, Hayashi RJ and (2023) Front. Oncol. 13:1280587. doi: 10.3389/fonc.2023.1280587

In the original article, there was an error in the author list order, as published. Instead of “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Robert J. Hayashi1, Rema Malone3”, It should be “Ema Mosleh1*, Stacy Snyder1†, Ningying Wu2, Daniel N. Willis1, Rema Malone3, Robert J. Hayashi1”.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: methotrexate, HDMTX, supportive care, delayed clearance, nephrotoxicity, adverse effect, pediatric cancer, AYA

Citation: Mosleh E, Snyder S, Wu N, Willis DN, Malone R and Hayashi RJ (2023) Corrigendum: Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients. Front. Oncol. 13:1333273. doi: 10.3389/fonc.2023.1333273

Received: 04 November 2023; Accepted: 08 November 2023;
Published: 27 November 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Mosleh, Snyder, Wu, Willis, Malone and Hayashi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Ema Mosleh, emosleh@wustl.edu

†Present address: Stacy Snyder, Beacon Health System, South Bend, IN, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.